|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000177294 |
Summary for FBXO39 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000177294 | Gene symbol | FBXO39 |
| Gene name | F-box protein 39 | |
| HGNC | 28565 | |
| Entrez ID | 162517 | |
| Gene type | protein_coding | |
| Synonyms | FBXO39|MGC35179|Fbx39|CT144 | |
| UniProtAcc | Q8N4B4 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for FBXO39 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for FBXO39 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for FBXO39 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg06091013 | chr17:6776163 | CGI:chr17:6775886-6776391 | promoter | 2.56e-01 | 4.69e-01 | -2.44e+00 | 1.48e-02 | 3.11e-02 | -2.13e-01 |
| BRCA | cg20723355 | chr17:6776278 | CGI:chr17:6775886-6776391 | promoter,gene body | 3.64e-01 | 6.01e-01 | -2.69e+00 | 7.05e-03 | 2.33e-02 | -2.36e-01 |
| BRCA | cg23729107 | chr17:6775945 | CGI:chr17:6775886-6776391 | promoter | 3.08e-01 | 4.86e-01 | -2.23e+00 | 2.58e-02 | 3.86e-02 | -1.78e-01 |
| BRCA | cg00376544 | chr17:6776029 | CGI:chr17:6775886-6776391 | promoter | 3.28e-01 | 5.06e-01 | -2.21e+00 | 2.68e-02 | 3.91e-02 | -1.78e-01 |
| BRCA | cg08843809 | chr17:6776165 | CGI:chr17:6775886-6776391 | promoter | 3.32e-01 | 5.40e-01 | -2.26e+00 | 2.40e-02 | 3.75e-02 | -2.08e-01 |
| BRCA | cg02093112 | chr17:6776176 | CGI:chr17:6775886-6776391 | promoter | 3.58e-01 | 5.99e-01 | -2.79e+00 | 5.33e-03 | 2.09e-02 | -2.40e-01 |
| BRCA | cg07540103 | chr17:6776180 | CGI:chr17:6775886-6776391 | promoter | 3.32e-01 | 5.82e-01 | -2.86e+00 | 4.24e-03 | 1.90e-02 | -2.50e-01 |
| BRCA | cg17097923 | chr17:6776222 | CGI:chr17:6775886-6776391 | promoter | 2.63e-01 | 4.65e-01 | -2.64e+00 | 8.25e-03 | 2.48e-02 | -2.02e-01 |
| BRCA | cg02374745 | chr17:6776245 | CGI:chr17:6775886-6776391 | UTR,promoter,exon,gene body | 4.15e-01 | 6.32e-01 | -2.73e+00 | 6.40e-03 | 2.25e-02 | -2.17e-01 |
| BRCA | cg21985295 | chr17:6776462 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.39e-01 | 2.60e-01 | -2.60e+00 | 9.30e-03 | 2.60e-02 | -1.20e-01 |
| BRCA | cg11871421 | chr17:6776157 | CGI:chr17:6775886-6776391 | promoter | 3.98e-01 | 6.19e-01 | -2.60e+00 | 9.34e-03 | 2.60e-02 | -2.21e-01 |
| GBM | cg20723355 | chr17:6776278 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.35e-01 | 2.36e-01 | -2.01e+00 | 4.40e-02 | 4.73e-02 | -1.01e-01 |
| GBM | cg23729107 | chr17:6775945 | CGI:chr17:6775886-6776391 | promoter | 1.39e-01 | 2.44e-01 | -2.26e+00 | 2.36e-02 | 3.81e-02 | -1.05e-01 |
| LAML | cg02093112 | chr17:6776176 | CGI:chr17:6775886-6776391 | promoter | 2.41e-01 | 3.43e-01 | -2.47e+00 | 1.34e-02 | 2.65e-02 | -1.02e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg06091013 | chr17:6776163 | CGI:chr17:6775886-6776391 | promoter | 1.43e-01 | 2.51e-02 | 6.27e+00 | 3.64e-10 | 5.91e-09 | 1.18e-01 |
| KIRC | cg23729107 | chr17:6775945 | CGI:chr17:6775886-6776391 | promoter | 1.75e-01 | 1.83e-02 | 6.42e+00 | 1.33e-10 | 3.14e-09 | 1.57e-01 |
| KIRC | cg00376544 | chr17:6776029 | CGI:chr17:6775886-6776391 | promoter | 1.74e-01 | 1.99e-02 | 5.58e+00 | 2.42e-08 | 1.51e-07 | 1.54e-01 |
| KIRC | cg08843809 | chr17:6776165 | CGI:chr17:6775886-6776391 | promoter | 2.11e-01 | 8.92e-02 | 4.74e+00 | 2.16e-06 | 7.12e-06 | 1.22e-01 |
| KIRC | cg17097923 | chr17:6776222 | CGI:chr17:6775886-6776391 | promoter | 1.79e-01 | 3.82e-02 | 6.55e+00 | 5.65e-11 | 1.95e-09 | 1.41e-01 |
| KIRC | cg21985295 | chr17:6776462 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.45e-01 | 3.75e-02 | 4.17e+00 | 3.06e-05 | 7.22e-05 | 1.08e-01 |
| KIRC | cg23341223 | chr17:6775935 | CGI:chr17:6775886-6776391 | promoter | 3.38e-01 | 1.86e-01 | 5.81e+00 | 6.34e-09 | 5.02e-08 | 1.52e-01 |
| LUAD | cg21985295 | chr17:6776462 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.90e-01 | 6.92e-02 | 2.31e+00 | 2.10e-02 | 2.46e-02 | 1.21e-01 |
| HNSC | cg06091013 | chr17:6776163 | CGI:chr17:6775886-6776391 | promoter | 2.03e-01 | 4.34e-02 | 3.93e+00 | 8.47e-05 | 2.26e-04 | 1.60e-01 |
| HNSC | cg23729107 | chr17:6775945 | CGI:chr17:6775886-6776391 | promoter | 1.98e-01 | 4.65e-02 | 2.78e+00 | 5.49e-03 | 7.70e-03 | 1.52e-01 |
| HNSC | cg00376544 | chr17:6776029 | CGI:chr17:6775886-6776391 | promoter | 2.21e-01 | 5.15e-02 | 3.32e+00 | 9.03e-04 | 1.66e-03 | 1.69e-01 |
| HNSC | cg08843809 | chr17:6776165 | CGI:chr17:6775886-6776391 | promoter | 2.76e-01 | 1.16e-01 | 3.33e+00 | 8.58e-04 | 1.59e-03 | 1.59e-01 |
| HNSC | cg02093112 | chr17:6776176 | CGI:chr17:6775886-6776391 | promoter | 2.62e-01 | 6.48e-02 | 3.57e+00 | 3.58e-04 | 7.60e-04 | 1.97e-01 |
| HNSC | cg07540103 | chr17:6776180 | CGI:chr17:6775886-6776391 | promoter | 2.40e-01 | 5.74e-02 | 3.36e+00 | 7.67e-04 | 1.45e-03 | 1.83e-01 |
| HNSC | cg17097923 | chr17:6776222 | CGI:chr17:6775886-6776391 | promoter | 2.06e-01 | 7.38e-02 | 3.12e+00 | 1.81e-03 | 3.01e-03 | 1.32e-01 |
| HNSC | cg02374745 | chr17:6776245 | CGI:chr17:6775886-6776391 | UTR,promoter,exon,gene body | 2.78e-01 | 8.53e-02 | 3.33e+00 | 8.80e-04 | 1.63e-03 | 1.93e-01 |
| HNSC | cg21985295 | chr17:6776462 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.37e-01 | 3.71e-02 | 2.69e+00 | 7.23e-03 | 9.72e-03 | 1.00e-01 |
| HNSC | cg23341223 | chr17:6775935 | CGI:chr17:6775886-6776391 | promoter | 3.55e-01 | 2.47e-01 | 2.20e+00 | 2.81e-02 | 3.07e-02 | 1.08e-01 |
| LUSC | cg13823366 | chr17:6775610 | CGI:chr17:6775886-6776391 | promoter | 7.12e-01 | 8.69e-01 | -2.99e+00 | 2.78e-03 | 5.29e-03 | -1.57e-01 |
| BLCA | cg06091013 | chr17:6776163 | CGI:chr17:6775886-6776391 | promoter | 2.71e-01 | 6.11e-02 | 2.32e+00 | 2.04e-02 | 2.48e-02 | 2.10e-01 |
| BLCA | cg20723355 | chr17:6776278 | CGI:chr17:6775886-6776391 | promoter,gene body | 3.31e-01 | 6.90e-02 | 2.43e+00 | 1.51e-02 | 1.96e-02 | 2.62e-01 |
| BLCA | cg23729107 | chr17:6775945 | CGI:chr17:6775886-6776391 | promoter | 2.41e-01 | 3.93e-02 | 2.44e+00 | 1.48e-02 | 1.92e-02 | 2.02e-01 |
| BLCA | cg00376544 | chr17:6776029 | CGI:chr17:6775886-6776391 | promoter | 2.64e-01 | 4.96e-02 | 1.99e+00 | 4.61e-02 | 4.69e-02 | 2.14e-01 |
| BLCA | cg08843809 | chr17:6776165 | CGI:chr17:6775886-6776391 | promoter | 3.46e-01 | 1.05e-01 | 3.24e+00 | 1.21e-03 | 2.64e-03 | 2.41e-01 |
| BLCA | cg02093112 | chr17:6776176 | CGI:chr17:6775886-6776391 | promoter | 3.50e-01 | 6.29e-02 | 2.62e+00 | 8.87e-03 | 1.28e-02 | 2.87e-01 |
| BLCA | cg07540103 | chr17:6776180 | CGI:chr17:6775886-6776391 | promoter | 3.22e-01 | 5.65e-02 | 2.58e+00 | 9.99e-03 | 1.41e-02 | 2.66e-01 |
| BLCA | cg17097923 | chr17:6776222 | CGI:chr17:6775886-6776391 | promoter | 2.68e-01 | 7.66e-02 | 2.05e+00 | 4.03e-02 | 4.23e-02 | 1.91e-01 |
| BLCA | cg02374745 | chr17:6776245 | CGI:chr17:6775886-6776391 | UTR,promoter,exon,gene body | 3.71e-01 | 9.68e-02 | 2.27e+00 | 2.34e-02 | 2.77e-02 | 2.74e-01 |
| BLCA | cg21985295 | chr17:6776462 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.73e-01 | 4.46e-02 | 2.12e+00 | 3.39e-02 | 3.70e-02 | 1.29e-01 |
| BLCA | cg13823366 | chr17:6775610 | CGI:chr17:6775886-6776391 | promoter | 7.50e-01 | 8.59e-01 | -2.23e+00 | 2.60e-02 | 3.01e-02 | -1.09e-01 |
| BLCA | cg23341223 | chr17:6775935 | CGI:chr17:6775886-6776391 | promoter | 3.83e-01 | 2.48e-01 | 2.06e+00 | 3.96e-02 | 4.17e-02 | 1.35e-01 |
| BLCA | cg11871421 | chr17:6776157 | CGI:chr17:6775886-6776391 | promoter | 3.91e-01 | 1.74e-01 | 2.37e+00 | 1.79e-02 | 2.24e-02 | 2.17e-01 |
| CHOL | cg00376544 | chr17:6776029 | CGI:chr17:6775886-6776391 | promoter | 3.96e-01 | 1.13e-01 | 1.99e+00 | 4.65e-02 | 4.65e-02 | 2.83e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg06091013 | chr17:6776163 | CGI:chr17:6775886-6776391 | promoter | 2.56e-01 | 3.88e-02 | 1.05e+01 | 8.77e-26 | 8.03e-25 | 2.17e-01 |
| BRCA | cg20723355 | chr17:6776278 | CGI:chr17:6775886-6776391 | promoter,gene body | 3.64e-01 | 5.08e-02 | 1.13e+01 | 1.57e-29 | 2.16e-28 | 3.14e-01 |
| BRCA | cg23729107 | chr17:6775945 | CGI:chr17:6775886-6776391 | promoter | 3.08e-01 | 3.91e-02 | 1.09e+01 | 1.85e-27 | 2.02e-26 | 2.69e-01 |
| BRCA | cg00376544 | chr17:6776029 | CGI:chr17:6775886-6776391 | promoter | 3.28e-01 | 5.04e-02 | 1.01e+01 | 6.99e-24 | 5.35e-23 | 2.78e-01 |
| BRCA | cg08843809 | chr17:6776165 | CGI:chr17:6775886-6776391 | promoter | 3.32e-01 | 1.22e-01 | 8.67e+00 | 4.26e-18 | 1.97e-17 | 2.10e-01 |
| BRCA | cg02093112 | chr17:6776176 | CGI:chr17:6775886-6776391 | promoter | 3.58e-01 | 4.99e-02 | 1.10e+01 | 5.37e-28 | 6.18e-27 | 3.08e-01 |
| BRCA | cg07540103 | chr17:6776180 | CGI:chr17:6775886-6776391 | promoter | 3.32e-01 | 4.22e-02 | 1.12e+01 | 3.97e-29 | 5.21e-28 | 2.90e-01 |
| BRCA | cg17097923 | chr17:6776222 | CGI:chr17:6775886-6776391 | promoter | 2.63e-01 | 5.99e-02 | 1.06e+01 | 2.13e-26 | 2.07e-25 | 2.03e-01 |
| BRCA | cg02374745 | chr17:6776245 | CGI:chr17:6775886-6776391 | UTR,promoter,exon,gene body | 4.15e-01 | 7.76e-02 | 1.08e+01 | 3.10e-27 | 3.29e-26 | 3.38e-01 |
| BRCA | cg21985295 | chr17:6776462 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.39e-01 | 3.66e-02 | 8.47e+00 | 2.38e-17 | 1.04e-16 | 1.03e-01 |
| BRCA | cg23341223 | chr17:6775935 | CGI:chr17:6775886-6776391 | promoter | 4.48e-01 | 2.52e-01 | 9.86e+00 | 6.42e-23 | 4.49e-22 | 1.96e-01 |
| BRCA | cg11871421 | chr17:6776157 | CGI:chr17:6775886-6776391 | promoter | 3.98e-01 | 1.38e-01 | 1.06e+01 | 2.05e-26 | 2.00e-25 | 2.60e-01 |
| LIHC | cg08843809 | chr17:6776165 | CGI:chr17:6775886-6776391 | promoter | 3.31e-01 | 1.29e-01 | 2.11e+00 | 3.50e-02 | 3.77e-02 | 2.01e-01 |
| KIRP | cg20723355 | chr17:6776278 | CGI:chr17:6775886-6776391 | promoter,gene body | 1.77e-01 | 3.65e-02 | 2.55e+00 | 1.08e-02 | 1.77e-02 | 1.40e-01 |
| KIRP | cg02093112 | chr17:6776176 | CGI:chr17:6775886-6776391 | promoter | 1.41e-01 | 2.84e-02 | 2.17e+00 | 3.01e-02 | 3.53e-02 | 1.12e-01 |
| KIRP | cg02374745 | chr17:6776245 | CGI:chr17:6775886-6776391 | UTR,promoter,exon,gene body | 1.93e-01 | 5.19e-02 | 2.25e+00 | 2.46e-02 | 3.07e-02 | 1.41e-01 |
Top |
Exon skipping events with PSI in TCGA for FBXO39 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for FBXO39 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for FBXO39 |
| TFs related to FBXO39. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | ZNF793 | FBXO39 | 4.25e+00 | 9.87e-01 | 2.41e+00 | 1.58e-03 | Male-biased |
| FBXO39 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for FBXO39 |
| RBPs related to ES in FBXO39. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| FBXO39 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of FBXO39 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
